IN2013MN01107A - - Google Patents

Download PDF

Info

Publication number
IN2013MN01107A
IN2013MN01107A IN1107MUN2013A IN2013MN01107A IN 2013MN01107 A IN2013MN01107 A IN 2013MN01107A IN 1107MUN2013 A IN1107MUN2013 A IN 1107MUN2013A IN 2013MN01107 A IN2013MN01107 A IN 2013MN01107A
Authority
IN
India
Prior art keywords
compounds
general formula
relates
cancer
prostate cancer
Prior art date
Application number
Inventor
Ian Weeks
Mohammed Jaffar
Richard Knox
Original Assignee
Univ Cardiff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cardiff filed Critical Univ Cardiff
Publication of IN2013MN01107A publication Critical patent/IN2013MN01107A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90209—Oxidoreductases (1.) acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)

Abstract

The invention relates to a method for diagnosing cancer, particularly bladder or prostate cancer using compounds of general formula (I): wherein R1, R2, R3, R4, R5 X, Y and z are as defined herein.
IN1107MUN2013 2010-12-20 2011-12-08 IN2013MN01107A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1021494.8A GB201021494D0 (en) 2010-12-20 2010-12-20 Compounds
PCT/GB2011/052430 WO2012085532A2 (en) 2010-12-20 2011-12-08 Methods and compounds for detecting cancer

Publications (1)

Publication Number Publication Date
IN2013MN01107A true IN2013MN01107A (en) 2015-06-12

Family

ID=43598602

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1107MUN2013 IN2013MN01107A (en) 2010-12-20 2011-12-08

Country Status (12)

Country Link
US (1) US20140370520A1 (en)
EP (1) EP2655653B1 (en)
CN (1) CN103492586A (en)
AU (1) AU2011346906B2 (en)
BR (1) BR112013015394A2 (en)
CA (1) CA2822369A1 (en)
DK (1) DK2655653T3 (en)
ES (1) ES2563097T3 (en)
GB (1) GB201021494D0 (en)
HK (1) HK1191062A1 (en)
IN (1) IN2013MN01107A (en)
WO (1) WO2012085532A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2678649T3 (en) 2011-10-14 2018-08-14 The Board Of Trustees Of The Universityof Illinois Compounds and substrates of nqo1 antitumor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003261204A1 (en) * 2002-07-23 2004-02-09 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
DE10303265A1 (en) * 2003-01-28 2004-07-29 Roche Diagnostics Gmbh Detecting analytes by a redox reaction and fluorescent measurement, useful for diagnosis, comprises using a fluorimetric redox indicator consisting of a linked fluorophore and quencher
AU2007213476B2 (en) * 2006-02-09 2013-03-28 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment involving determination of tumor enzyme level
WO2009006577A2 (en) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
TWI354101B (en) * 2008-08-19 2011-12-11 Univ Nat Taipei Technology Fluorimetric indicator for biosensing and manufact
WO2011113018A1 (en) * 2010-03-12 2011-09-15 Ampere Life Sciences, Inc. Measurement and control of biological time

Also Published As

Publication number Publication date
DK2655653T3 (en) 2016-02-22
CA2822369A1 (en) 2012-06-28
CN103492586A (en) 2014-01-01
US20140370520A1 (en) 2014-12-18
ES2563097T3 (en) 2016-03-10
WO2012085532A3 (en) 2012-08-16
BR112013015394A2 (en) 2016-09-20
AU2011346906A1 (en) 2013-07-04
AU2011346906B2 (en) 2016-03-03
HK1191062A1 (en) 2014-07-18
EP2655653B1 (en) 2015-11-18
EP2655653A2 (en) 2013-10-30
GB201021494D0 (en) 2011-02-02
WO2012085532A2 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
MX341133B (en) Compounds and methods.
MX341456B (en) Amino-quinolines as kinase inhibitors.
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
IN2015DN00960A (en)
IN2012DN02751A (en)
MY169043A (en) New dihydroquinoline-2-one derivatives
MX2014014531A (en) Aminoquinazoline and pyridopyrimidine derivatives.
MX2012008141A (en) Compounds and methods.
EP2566477A4 (en) Amino-quinolines as kinase inhibitors
MX2014001879A (en) Amino quinazolines as kinase inhibitors.
EA201170154A1 (en) DERIVATIVES OF PYRIDINOPIRIDINONES, METHOD OF THEIR RECEPTION AND APPLICATION IN THERAPY
PH12015500345A1 (en) Amino-quinolines as kinase inhibitors
MY169267A (en) New aryl-quinoline derivatives
IN2012DN01342A (en)
MX339300B (en) Small molecule inhibitors of n-terminus activation of the androgen receptor.
TN2013000354A1 (en) Synthesis of 2-carboxamide cycloamino urea derivatives
HK1124842A1 (en) Methods of preparing imidazole-based compounds
IN2012DN05081A (en)
MX2012007835A (en) 2,5,7-substituted oxazolopyrimidine derivatives.
MX2012005155A (en) Quinazoline compounds.
MX342311B (en) New azaspirodecanone compounds as hsl inhibitors.
IN2013MN01107A (en)
UA34487U (en) Aquananomagnesium
GB201309029D0 (en) 3-arylethynyl substituted quinazolinone compounds
MX344429B (en) New hexahydropyrroloimidazolone compounds.